drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified cellular therapy composed of a dual population of CD5-knockout T cells and CD5-knockout anti-CD5 CAR-T cells, engineered to target CD5+ malignant T cells and prevent fratricide; administered as a single IV infusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene-edited therapy comprising CD5-knockout anti-CD5 CAR-T cells (plus CD5-knockout T cells) that recognize CD5 on malignant T cells. CAR engagement activates T-cell cytotoxicity to kill CD5+ tumor cells, while CD5 knockout prevents fratricide and may relieve inhibitory CD5 signaling to enhance persistence and function.
drug_name
Senza5 CART5
nct_id_drug_ref
NCT06420089